---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-032028"
form_type: "8-K"
ticker: "RCKT"
cik: "0001281895"
company_name: "ROCKET PHARMACEUTICALS, INC."
filed_at: "2026-08-10T20:17:18+00:00"
generated_at: "2026-08-10T20:18:24.256377+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Rocket Pharma Q2 net income $123.2M on PRV sale; cash $283.7M, runway to Q2 2028

## Summary
- Net income $123.2M ($1.09 basic EPS) vs net loss $68.9M ($0.62 loss) in Q2 2025.
- Other income $178.8M includes $178.2M net from Rare Pediatric Disease PRV sale (closed June 12, 2026).
- RP-A501: all 3 initial Danon disease patients completed safety observation; no TMA or capillary leak.
- KRESLADI (LAD-I) FDA approved; commercial availability and patient onboarding expected Q4 2026.
- Cash $283.7M at June 30, 2026; expected to fund operations into Q2 2028.

## SEC filing metadata
- accession: 0001140361-26-032028
- form_type: 8-K
- ticker: RCKT
- cik: 0001281895
- company_name: ROCKET PHARMACEUTICALS, INC.
- filed_at: 2026-08-10T20:17:18+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1281895/000114036126032028/0001140361-26-032028-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1281895/000114036126032028/ef20079821_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-032028
- JSON: https://secwatch.observer/filing/0001140361-26-032028.json
- Plain text: https://secwatch.observer/filing/0001140361-26-032028.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.